Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab modulation of irradiated rectal telangiectasia
NL-OMON22711Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in rectal cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Microvascular histology. Started Dec 2011; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON22711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22711.